Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BioCryst Pharmaceuticals 4Q 2025 Earnings Call - ORLADEYO momentum fuels profit while navenibart aims to lock HAE prophylaxis decision
BioCryst closed 2025 with clear commercial traction and a tidy operating story. ORLADEYO delivered $601.8 million in revenue, up 38% year over year and 43% excluding the European business sold in Octo...
- ORLADEYO posted $601.8 million in 2025 revenue, up 38% year over year and 43% when excluding the European business sold in October 2025.
- Management is emphasizing profitability and disciplined capital allocation under new CEO Charlie Gayer, who called BioCryst a focused, profitable rare disease company.
- BioCryst stripped out its European ORLADEYO business, which was loss making, improving base margins and simplifying the commercial footprint.
- +12 more takeaways
Blend Labs, Inc Q4 2025 Earnings Call - Debuts Autopilot agent as company returns to profitability and ups buyback
Blend closed Q4 2025 showing a lean, cash-positive profile and a strategic pivot toward agentic AI. Revenue was $32.4 million with $5.4 million in non-GAAP operating income, positive free cash flow fo...
- Q4 revenue $32.4 million, non-GAAP operating income $5.4 million, non-GAAP operating margin 17%.
- Mortgage Suite revenue $18.8 million, up 3% year-over-year; funded loan volume grew 11% in Q4; Economic Value per Funded Loan (EVPFL) was $83.
- Consumer Banking Suite revenue $11.5 million, up 21% year-over-year but down 10% sequentially due to one large customer churn and home equity seasonality.
- +12 more takeaways
Cheniere Energy Fourth Quarter and Full Year 2025 Earnings Call - Upsized $10B Buyback After Early Completion of 2020 Plan and >95% Contracted Platform
Cheniere closed 2025 with record volumes, strong cash generation and accelerated execution on both operations and capital allocation. The company reported Q4 consolidated adjusted EBITDA of about $2.0...
- Q4 consolidated adjusted EBITDA approximately $2.0 billion; full-year 2025 adjusted EBITDA about $6.94 billion, at the high end of guidance.
- Distributable cash flow roughly $1.5 billion in Q4 and about $5.3 billion for the full year, about $100 million above the high end of guidance.
- Record 2025 production: 670 cargoes, over 46 million tons; Q4 exported 185 cargoes, up 22 versus Q3 driven by Stage 3 volumes and improved reliability.
- +12 more takeaways
GeoPark Limited 4Q 2025 Earnings Call - Transformational Frontera deal and Vaca Muerta ramp reposition company for scale by 2028
GeoPark closed 2025 with stabilizing Colombian production and an early Argentina contribution, hitting or beating full-year guidance despite a weaker oil price. Production averaged 28,233 boepd in 202...
- Transformational M&A: GeoPark announced an agreed acquisition of Frontera’s Colombian upstream assets in January, which doubles its reserve base and brings pro forma net production of ~40,000 boepd, materially boosting scale and cash flow durability.
- Pro forma upside to 2028: Management says the Frontera deal plus current plans could push company production to exceed 90,000 boepd by 2028 and pro forma Adjusted EBITDA near $950 million, versus standalone targets of 44,000-46,000 boepd and $490-$520 million Adjusted EBITDA by 2028.
- Vaca Muerta entry is live: GeoPark closed Loma Jarillosa Este and Puesto Silva Oeste blocks in October, started workovers and will mobilize a Nabors rig in early March to drill a five-well pad, targeting an Argentina exit rate of 5,000-6,000 boepd in 2026 and a 20,000 boepd plateau by 2028.
- +11 more takeaways
Origin Materials Q4 2025 Earnings Call - PET cap progress meets tests, but cash runway only into Q3 2026
Origin reported tangible product progress this quarter, delivering a new PET cap iteration to roughly 30 prospects and achieving internal test improvements on seal performance, impact resistance, and ...
- New PET cap iteration was delivered this month to about 30 prospective customers, incorporating customer feedback and showing marked improvements in internal seal and impact tests.
- Origin claims its PET caps meet industry benchmarks for pressurized water applications on ball impact and heat stress testing, and performed comparably to HDPE caps in a live retail pilot with Power Hydration.
- Customer qualification remains the choke point, taking longer than Origin had modeled, driven by bespoke testing requirements and unfamiliarity with a PET cap geometry versus HDPE.
- +9 more takeaways
Braskem Q4 2025 2025 Earnings Call - EBITDA Down 49%, Leverage at 14.74x, $2.1bn Cash as Restructuring Looms
Braskem delivered a bruising set of results for 2025, with recurring consolidated EBITDA plunging to $557 million, down 49% versus 2024, and Q4 recurring EBITDA of $109 million. The industrywide overs...
- Recurring consolidated EBITDA for Q4 2025 was $109 million, and recurring consolidated EBITDA for FY2025 was $557 million, a 49% decline versus 2024.
- Operating cash generation in Q4 was approximately $13 million, while the company reported operating cash consumption of $246 million for the year in USD terms and BRL 1.4 billion in local currency terms.
- Corporate cash at 31 Dec 2025 totaled about $2.1 billion, which includes a $1.0 billion standby facility drawn in October that matures in December 2026.
- +12 more takeaways
Carnival Corporation First Quarter 2026 Earnings Call - PROPEL launched: big returns target and $2.5bn buyback, even as fuel spike dents 2026
Carnival rode strong demand into Q1, reporting record revenues, higher yields and a $275 million net income, while customer deposits hit a near $8 billion first quarter high. Management used the momen...
- Q1 2026 delivered record first quarter revenues, net yields up 2.7% year over year, and net income of $275 million, about 55% higher than prior year.
- Customer deposits reached almost $8 billion in Q1, a new first quarter record and roughly 10% higher than last year, reflecting earlier guest engagement and heavier pre-cruise sales.
- Bookings for current year sailings rose roughly 10% year over year, leaving nearly 85% of 2026 capacity already on the books and future-year bookings also at a first quarter record.
- +12 more takeaways
Legence Q4 2025 Earnings Call - Record revenue and backlog driven by data center fabrication and Bowers acquisition
Legence closed 2025 with a blowout quarter, reporting Q4 revenue of $738 million, up 35% year over year, and record backlog and awards of $3.7 billion, up nearly 50% year over year. Management says mo...
- Q4 2025 revenue $738 million, up 35% year over year, quarter was well ahead of prior guidance.
- Full year 2025 revenue $2.6 billion, up 22%; adjusted EBITDA for FY2025 $299 million, up 30% year over year.
- Q4 adjusted EBITDA $87 million, up 53% year over year; adjusted EBITDA margin improved ~140 basis points to 11.8% in the quarter.
- +16 more takeaways
Southland Q4 2025 Earnings Call - Sureties step in after $136M Washington State Convention Center charge
Southland reported a brutal Q4 and full-year 2025, with revenue for the quarter of $104 million and a $193 million gross loss driven by legacy-project writedowns. The headline charge was a $136 millio...
- Q4 revenue was $104 million, but that figure includes a $92 million revenue reversal tied to legacy dispute adjustments.
- Reported Q4 gross loss was $193 million, sharply worse than prior year Q4 gross profit of $8 million.
- A $136 million adverse trial ruling on the Washington State Convention Center (WSCC) project was the primary driver of the charge, including an $85 million judgment, $40 million reversal of an expected recovery, $6.4 million retention, and $4.8 million related to a sanctions order as described by management.
- +11 more takeaways
Autolus Therapeutics Q4 2025 Earnings Call - Strong first-year AUCATZYL sales ($74M) validate launch but scaling, margins and cash runway become the next test
Autolus closed 2025 with a credible first commercial year for AUCATZYL, recognizing $74.3 million in net product revenue and activating 67 treatment centers. Management reiterated 2026 guidance of $12...
- AUCATZYL first full year revenue in 2025 was $74.3 million, with Q4 product revenue of $23.3 million and total Q4 revenue $24.3 million including a $1 million Moderna milestone.
- Company reiterates 2026 net revenue guidance of $120 million to $135 million and targets more than 80 activated centers by year-end 2026, up from 67 at end-2025.
- Autolus expects to shift to positive gross margins in 2026, driven by higher volumes that spread fixed costs and by operational improvements to lower variable cost per batch.
- +11 more takeaways